Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Rapt Therapeutics Inc (NQ: RAPT )

1.210 +0.090 (+8.04%)
Streaming Delayed Price Updated: 2:32 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Rapt Therapeutics Inc

< Previous 1 2 3 4 5 Next >
Why International Flavors & Fragrances Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of International Flavors & Fragrances Inc. (NYSE: IFF) fell during Wednesday’s session after the company reported mixed fourth-quarter financial results and reduced its expected quarterly... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Stocks Slip Ahead Of Fed Minutes, Nvidia Earnings
Stocks are lower today, with the Nasdaq Composite Index (IXIC) leading the losses as investors reassess a potentially overvalued tech sector. 
Via Talk Markets
Topics Economy Stocks
Exposures Interest Rates US Equities
Recap: RAPT Therapeutics Q3 Earnings
Via Benzinga
Analyst Ratings for RAPT Therapeutics
Via Benzinga
Crude Oil Moves Lower; Summit Therapeutics Shares Plummet
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling over 200 points on Tuesday. The Dow traded down 0.18% to 38,557.86 while the NASDAQ fell 1.30% to 15,570.84. The... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why Fluor Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Fluor Corporation (NYSE: FLR) fell during Tuesday’s session following fourth-quarter results. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
The Latest Analyst Ratings for RAPT Therapeutics
Via Benzinga
Why Is Inflammatory Disease/Oncology-Focused RAPT Therapeutics Shares Tumbling Today?
FDA places clinical hold on RAPT Therapeutics' Phase 2 trials for zelnecirnon in atopic dermatitis and asthma. 
Via Benzinga
Exposures Product Safety
Rapt Therapeutics Crashes 65% After Unexpected Liver Failure Sidelines Two Tests
The FDA put studies in eczema and asthma treatment on clinical hold. 
Via Investor's Business Daily
Exposures Product Safety
Dow Dips Over 100 Points; US Leading Economic Index Falls In January
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 1.5% on Tuesday. The Dow traded down 0.35% to 38,494.51 while the NASDAQ fell 1.51% to 15,537.95. The S&P 500... 
Via Benzinga
Topics Stocks
Exposures US Equities
Dow Rebounds; Nasdaq Drops Triple Digits
Nvidia stock is sliding ahead of tomorrow's earnings report 
Via Talk Markets
Topics Stocks
Exposures US Equities
Nasdaq Down 1%; Capital One Set To Buy Discover
U.S. stocks traded lower this morning, with the Nasdaq Composite falling around 150 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.05% to 38,607.53 while the NASDAQ fell... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Reports Third Quarter 2023 Financial Results
Company maintains strong cash position of $184.8 million 
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in November
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Announces Two FLX475 Presentations at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
From RAPT Therapeutics, Inc.
Via GlobeNewswire
7 ‘Strong Buy’ Biotech Stocks to Rejuvenate Your Portfolio
Dive into these seven strong buy biotech stocks, handpicked by Wall Street, to inject vigor into your investment game. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2023
Via Benzinga
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Reports Second Quarter 2023 Financial Results
Company maintains strong cash position of $205 million 
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2023
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.